Sylwia Niemyjska
Research Interests
Sylwia Niemyjska has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Przylipiak
Department of Esthetic Medicine Faculty of Pharmacy Medical University of Białystok Bialystok Poland
1 shared publication - Emilia Lubowicka
Department of Aesthetic Medicine, Medical University of Bialystok, 15-267 Bialystok, Poland
1 shared publication - Monika Zajkowska
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
1 shared publication - Orest Szczygielski
Clinic of Paediatric Surgery, Institute of Mother and Child, Kasprzaka Str 17a, 01-211 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 18 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13558
Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma
Malignant melanoma is one of the most important dermatological neoplasms. The high mortality rate associated with this skin disease is primarily due to the occurrence of metastases, while the diagnosis and treatment of melanoma in its early stages has a favorable prognosis. Early detection is crucial because the success of treatment is directly related to the depth of cancerous growth. The family of matrix metalloproteinases (MMPs) plays a critical role in the initiation and progression of melanoma. Prominent MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and MMP-14, have been shown to significantly contribute to the development of melanoma. The tumor microenvironment, particularly the extracellular matrix (ECM), has emerged as a critical factor in modulating cancer progression. This review focuses on the role of matrix metalloproteinases and their inhibitors in ECM degradation and the subsequent progression of melanoma, as well as their potential as therapeutic targets.
- 18 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13558
Open AccessTargeting Matrix Metalloproteinases and Their Inhibitors in Melanoma
Malignant melanoma is one of the most important dermatological neoplasms. The high mortality rate associated with this skin disease is primarily due to the occurrence of metastases, while the diagnosis and treatment of melanoma in its early stages has a favorable prognosis. Early detection is crucial because the success of treatment is directly related to the depth of cancerous growth. The family of matrix metalloproteinases (MMPs) plays a critical role in the initiation and progression of melanoma. Prominent MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and MMP-14, have been shown to significantly contribute to the development of melanoma. The tumor microenvironment, particularly the extracellular matrix (ECM), has emerged as a critical factor in modulating cancer progression. This review focuses on the role of matrix metalloproteinases and their inhibitors in ECM degradation and the subsequent progression of melanoma, as well as their potential as therapeutic targets.